Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20799620 | 0.79 | PLAU (0.33) | PLAU | |
| SCHEMBL362613 | 0.77 | PLAU (0.32) | PLAU | |
| SCHEMBL31471091 | 0.77 | PLAU (0.32) | PLAU | |
| SCHEMBL17427737 | 0.71 | LMNA (0.39) | — | |
| SCHEMBL589119 | 0.67 | ALDH1A1 (0.32) | PLAU | |
| SCHEMBL29118278 | 0.67 | — | — | |
| SCHEMBL28965611 | 0.67 | ALDH1A1 (0.41) | — | |
| SCHEMBL67272 | 0.67 | PLAU (0.43) | PLAU | |
| SCHEMBL11601454 | 0.64 | PLAU (0.37) | PLAU | |
| SCHEMBL1565254 | 0.64 | KHK (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8628751-B2 | Pyrazine derivatives for optical imaging and therapy | Medi Beacon Development, LLC (US) | 2014-01-14 | — | — | US | disclosed |
| US-8628751-B2 | Pyrazine derivatives for optical imaging and therapy | Medi Beacon Development, LLC (US) | 2014-01-14 | — | — | US | disclosed |
| US-20120027682-A1 | Pyrazine Derivatives for Optical Imaging and Therapy | MEDIBEACON, INC. | 2012-02-02 | — | — | US | disclosed |
| US-20120027682-A1 | Pyrazine Derivatives for Optical Imaging and Therapy | MEDIBEACON, INC. | 2012-02-02 | — | — | US | disclosed |
| WO-2010121003-A1 | PYRAZINE DERIVATIVES FOR OPTICAL IMAGING AND THERAPY | MALLINCKRODT INC. (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027682-A1 | Pyrazine Derivatives for Optical Imaging and Therapy | CYP3A5, SSTR5, IL15 | PLAU 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.